NAFLD is where NASH starts but it doesn't necessar
Post# of 148179
The proper way to do it is to look at NASH vs. NASH which I outlined here -
https://investorshangout.com/post/view?id=6331942
I've previously said the 350mg results were good but not great but even those results seem to be more than a match for Madrigal. The problem for comparison is incomplete data from both companies.
The matchup is from Cytodyn's 14 week trial vs. Madrigal's 52 week data. Longer usage of leronlimab should skew the data better for leronlimab especially in MRI-PDFF.
Knowing that leronlimab has always shown better effect at the higher dose it would not surprise me to see a 10% to 15% better result from 700mg than from 350mg.